亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 5477: AI-driven de novo design of miniproteins targeting mutant p53 peptide-MHC-I complex for cancer immunotherapy.

突变体 错义突变 癌症 生物 癌症研究 癌细胞 突变 癌症免疫疗法 免疫疗法 人口 突变蛋白 抗原 融合蛋白 MHC I级 主要组织相容性复合体 分子生物学 嵌合抗原受体 免疫学 抑制器 抗体 等位基因 单克隆抗体 抑癌基因 免疫系统 表位
作者
Fengze Jin,Puja Singh,Hanyong Chen,Christopher A. Warlick,Yibin Deng
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 5477-5477
标识
DOI:10.1158/1538-7445.am2026-5477
摘要

Abstract Genetic alterations in the tumor suppressor p53 occur in nearly every type of human cancer, with mutation rates ranging from 10% to nearly 100%, averaging about 50% in cancer patients. Over 80% of these mutations are missense mutations in the p53 DNA-binding domain (DBD), with the p53-R175H mutation being the most common "hot spot," occurring in approximately 5% of p53-mutated cases. Clinically, p53-R175H mutation in cancer patients are significantly associated with decreased overall survival compared to cancer patients with wild-type p53. Biologically, missense mutations in the p53 gene, particularly "hot-spot" mutations, including p53-R175H, result in the high expression of mutant p53 protein in cancer cells. These features suggest that expression of mutant p53-R175H protein could serve as an attractive therapeutic target. However, targeting the intracellular oncoprotein mutant p53-R175H has proven extremely challenging and remains a major unmet need in cancer therapy. Interestingly, the mutant p53-R175H protein can be processed by the proteasome into a 9-mer peptide, presented on the cancer cell surface by human leukocyte antigen (HLA)-A*02:01, a common major histocompatibility complex (MHC) class I allele in the U.S. population (40%), providing a “unique” target for immunotherapy by harnessing immune cells—such as T cells—to eliminate cancer cells carrying mutant p53R-175H. Traditional efforts to develop T cell receptors (TCRs) or monoclonal antibodies (mAbs) against the peptide-MHC-I complex have largely failed due to low affinity, limited specificity, and multi-year development timelines. Recent advances demonstrate that artificial intelligence (AI)-designed miniproteins (less than 150 amino acids) targeting peptide-MHC class I complexes can be engineered into chimeric antigen receptor (CAR)-T cells, enabling robust T-cell activation and potent recognition and elimination of tumor cells. To accelerate the discovery of miniprotein-mediated therapeutics, we have developed and integrated multiple AI-driven platforms for de novo design of p53-R175H peptide-MHC-I-complex binding miniproteins, including diverse backbone generation, protein sequence optimization, and enhanced high-throughput computational screening of peptide-MHC-I-miniprotein complexes. Top candidates have undergone, or are currently undergoing, experimental validation as engineered T/NK cell engagers and CAR-T/NK cells to kill cancer cells. In summary, our integrated AI-driven framework enables rapid and personalized cancer immunotherapy by transforming previously “undruggable” intracellular oncoproteins—including, but not limited to, mutant p53—into actionable immunotherapeutic targets. Citation Format: Fengze Jin, Puja Singh, Hanyong Chen, Christopher Warlick, Yibin Deng, . AI-driven de novo design of miniproteins targeting mutant p53 peptide-MHC-I complex for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5477.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在喝咖啡ing完成签到,获得积分10
3秒前
共享精神的应助被稳重又琴采纳,获得60
4秒前
万能图书馆的应助被Louislee采纳,获得10
7秒前
8秒前
sjn完成签到,获得积分10
10秒前
11秒前
cccsh完成签到 ,获得积分10
12秒前
13秒前
舒服的荧完成签到,获得积分10
14秒前
14秒前
思源的应助被labor采纳,获得30
15秒前
ldxghh发布了新的文献求助10
17秒前
香蕉觅云的应助被thisXiao6采纳,获得10
21秒前
科研通AI6.3的应助被刻苦灯泡采纳,获得10
23秒前
yy完成签到 ,获得积分10
28秒前
PeizeWu完成签到,获得积分10
29秒前
二氧化碳喲完成签到,获得积分10
30秒前
31秒前
浅荫完成签到,获得积分10
33秒前
thisXiao6发布了新的文献求助10
36秒前
斯文尔珍完成签到,获得积分10
39秒前
小华完成签到 ,获得积分10
41秒前
小二郎的应助被hyxiaoren采纳,获得20
44秒前
49秒前
隐形的冷亦完成签到,获得积分10
53秒前
盒子的应助被thisXiao6采纳,获得30
54秒前
labor发布了新的文献求助30
54秒前
55秒前
56秒前
852的应助被亚历山大采纳,获得10
56秒前
58秒前
1分钟前
cxw陈祥薇完成签到 ,获得积分10
1分钟前
刻苦灯泡发布了新的文献求助10
1分钟前
1分钟前
小鱼儿发布了新的文献求助10
1分钟前
郑嘉辉完成签到 ,获得积分10
1分钟前
稳重又琴发布了新的文献求助60
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780029
捐赠科研通 7764837
什么是DOI,文献DOI怎么找? 3431499
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476579